India, June 23 -- Shares of Cidara Therapeutics, Inc. (CDTX) were surging around 86 percent in the pre-market activity on the Nasdaq, after the biotechnology company announced Monday positive topline results from its Phase 2b NAVIGATE trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64.
The study met its primary and all secondary efficacy endpoints for all dose groups. The company has submitted end of Phase 2 meeting request to the U.S. Food and Drug Administration to review the results and further discuss the Phase 3 trial design and start time.
The company, which applies its proprietary Cloudbreakplatform to develop drug-Fc conjugate (DFC) therapeutics, noted that the randomized, ...